These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1540057)

  • 1. Iron chelation in myocardial preservation after ischemia-reperfusion injury: the importance of pretreatment and toxicity.
    DeBoer DA; Clark RE
    Ann Thorac Surg; 1992 Mar; 53(3):412-8. PubMed ID: 1540057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A promising approach for improving the recovery of heart transplants. Prevention of free radical injury through iron chelation by deferoxamine.
    Menasché P; Grousset C; Mouas C; Piwnica A
    J Thorac Cardiovasc Surg; 1990 Jul; 100(1):13-21. PubMed ID: 2366551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A new concept of cardioplegic protection in cardiac surgery: iron chelation].
    Menasché P; Grousset C; Gauduel Y; Mouas C; Piwnica A
    Arch Mal Coeur Vaiss; 1988 Jun; 81(6):811-6. PubMed ID: 3144954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acadesine and myocardial protection. Studies of time of administration and dose-response relations in the rat.
    Galiñanes M; Mullane KM; Bullough D; Hearse DJ
    Circulation; 1992 Aug; 86(2):598-608. PubMed ID: 1638725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of postischemic myocardial function and metabolism induced by administration of deferoxamine at the time of reflow: the role of iron in the pathogenesis of reperfusion injury.
    Ambrosio G; Zweier JL; Jacobus WE; Weisfeldt ML; Flaherty JT
    Circulation; 1987 Oct; 76(4):906-15. PubMed ID: 2820615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient hypocalcemic reperfusion does not improve postischemic recovery in the rat heart after preservation with St. Thomas' Hospital cardioplegic solution.
    Chambers DJ; Harvey DM; Braimbridge MV; Hearse DJ
    J Thorac Cardiovasc Surg; 1992 Aug; 104(2):344-56. PubMed ID: 1495296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with deferoxamine during ischemia improves functional and metabolic recovery and reduces reperfusion-induced oxygen radical generation in rabbit hearts.
    Williams RE; Zweier JL; Flaherty JT
    Circulation; 1991 Mar; 83(3):1006-14. PubMed ID: 1847847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of hydroxyl radical formation: a critical concept for improving cardioplegia. Protective effects of deferoxamine.
    Menasche P; Grousset C; Gauduel Y; Mouas C; Piwnica A
    Circulation; 1987 Nov; 76(5 Pt 2):V180-5. PubMed ID: 2822288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of sodium pump activity in warm induction of cardioplegia combined with reperfusion of oxygenated cardioplegic solution.
    Ko T; Otani H; Imamura H; Omori K; Inagaki C
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):103-10. PubMed ID: 7609533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiradical effects in L-propionyl carnitine protection of the heart against ischemia-reperfusion injury: the possible role of iron chelation.
    Reznick AZ; Kagan VE; Ramsey R; Tsuchiya M; Khwaja S; Serbinova EA; Packer L
    Arch Biochem Biophys; 1992 Aug; 296(2):394-401. PubMed ID: 1321584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferoxamine, an iron chelator, reduces myocardial injury and free radical generation in isolated neonatal rabbit hearts subjected to global ischaemia-reperfusion.
    Katoh S; Toyama J; Kodama I; Akita T; Abe T
    J Mol Cell Cardiol; 1992 Nov; 24(11):1267-75. PubMed ID: 1336063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose iron-chelator therapy during reperfusion with deferoxamine-hydroxyethyl starch conjugate fails to reduce canine infarct size.
    Lesnefsky EJ; Hedlund BE; Hallaway PE; Horwitz LD
    J Cardiovasc Pharmacol; 1990 Oct; 16(4):523-8. PubMed ID: 1706792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related differences in cardiac susceptibility to ischemia/reperfusion injury. Response to deferoxamine.
    Nakamura H; del Nido PJ; Jimenez E; Sarin M; Feinberg H; Levitsky S
    J Thorac Cardiovasc Surg; 1992 Jul; 104(1):165-72. PubMed ID: 1614203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardioplegic arrest superimposed on evolving myocardial ischemia. Improved recovery after inhibition of hydroxyl radical generation by peroxidase or deferoxamine. A 31P nuclear resonance study.
    Bernard M; Menasché P; Piétri S; Grousset C; Piwnica A; Cozzone PJ
    Circulation; 1988 Nov; 78(5 Pt 2):III164-72. PubMed ID: 2846203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferoxamine pretreatment reduces canine infarct size and oxidative injury.
    Lesnefsky EJ; Repine JE; Horwitz LD
    J Pharmacol Exp Ther; 1990 Jun; 253(3):1103-9. PubMed ID: 2359019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs.
    Hurn PD; Koehler RC; Blizzard KK; Traystman RJ
    Stroke; 1995 Apr; 26(4):688-94; discussion 694-5. PubMed ID: 7709418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of L-carnitine on myocardial protection in cold cardioplegia followed by reperfusion.
    Nakagawa T; Sunamori M; Suzuki A
    Thorac Cardiovasc Surg; 1994 Apr; 42(2):85-9. PubMed ID: 8016834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance of the myocardial thiol pool by N-acetylcysteine. An effective means of improving cardioplegic protection.
    Menasché P; Grousset C; Gauduel Y; Mouas C; Piwnica A
    J Thorac Cardiovasc Surg; 1992 May; 103(5):936-44. PubMed ID: 1569775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against injury during ischemia and reperfusion by acadesine derivatives GP-1-468 and GP-1-668. Studies in the transplanted rat heart.
    Galiñanes M; Zhai X; Bullough D; Mullane KM; Hearse DJ
    J Thorac Cardiovasc Surg; 1995 Sep; 110(3):752-61. PubMed ID: 7564443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferoxamine, the newly developed iron chelator LK-614 and N-alpha-acetyl-histidine in myocardial protection.
    Koch A; Loganathan S; Radovits T; Sack FU; Karck M; Szabó GB
    Interact Cardiovasc Thorac Surg; 2010 Feb; 10(2):181-4. PubMed ID: 19914924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.